Mediators of Inflammation

Volume 2013 (2013), Article ID 145197, 9 pages

http://dx.doi.org/10.1155/2013/145197

Research Article

PGE₂ Desensitizes β-Agonist Effect on Human Lung Fibroblast-Mediated Collagen Gel Contraction through Upregulating PDE4

Qiuhong Fang,1,2 Yingmin Ma,¹ Jing Wang,¹ Joel Michalski,² Stephen I. Rennard,² and Xiangde Liu²

¹Department of Pulmonary and Critical Care, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

²Pulmonary, Critical Care, Sleep and Allergy Division, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-5910, USA

Received 10 July 2013; Accepted 1 September 2013

Academic Editor: Céline Méhats

Copyright © 2013 Qiuhong Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

In the current study, we investigated the effect of a long-acting β-agonist (salmeterol) and a phosphodiesterase 4 (PDE4) inhibitor (cilomilast) on human lung fibroblast-mediated collagen gel contraction. Higher concentrations of salmeterol (10⁻⁷ and 10⁻⁶ M) inhibited fibroblast-mediated collagen gel contraction. No effect was observed with cilomilast alone (up to 10⁻⁵ M). In the presence of 10⁻⁸ M salmeterol, however, cilomilast could significantly inhibit fibroblast-mediated collagen gel contraction in a concentration-dependent manner (10⁻⁷~10⁻⁵ M). Blockade of endogenous PGE₂ by indomethacin further potentiated the inhibitory effect of salmeterol on fibroblast-mediated collagen gel contraction, but it did not affect cilomilast's effect. Pretreatment with PGE₂ abolished the inhibitory effect of salmeterol, but it potentiated the inhibitory effect of cilomilast on fibroblast-mediated collagen gel contraction. Finally, indomethacin slightly inhibited PDE4C expression, while PGE₂ stimulated the expression of PDE4A and -4C in human lung fibroblasts. These findings suggest that long-acting β-agonist and PDE4 inhibitor have a synergistic effect in regulating fibroblast tissue repair functions and that PGE₂ can modulate the effect of β-agonist and PDE4 inhibitor at least in part through the mechanism of regulating PDE4 expression.

1. Introduction

Lung fibroblasts play an important role in the repair processes following lung injury and contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). Impaired repair function of lung fibroblasts could result in emphysema, while overproduction of extracellular matrix by fibroblasts may lead to peribronchial fibrosis, both of which are major pathologic characteristics of COPD [1, 2]. Fibroblast-mediated collagen gel contraction is an in vitro model of tissue remodeling and is widely used to investigate repair functions of fibroblasts from a variety of tissues including lung and skin [3, 4].

Fibroblast-mediated collagen gel contraction can be modulated by many factors. For example, TGF-1 and PDGF are potent stimulators of fibroblast-mediated collagen gel contraction, while prostaglandin E₂ (PGE₂) and -adrenergic agonists are inhibitors of this process [5–8]. The inhibitory effect of -agonist exposure on fibroblast-mediated collagen gel contraction is based on increased intracellular cAMP levels [7]. Lung fibroblasts are also important sources of PGE₂, which modulates the level of intracellular cAMP levels and thus modulates repair functions through autocrine and paracrine pathways [2, 9].

The intracellular level of cAMP is also dependent on its rate of degradation. Phosphodiesterases (PDEs) are enzymes that degrade cAMP through hydrolysis. PDEs comprise 11 related gene families that have been classified according to their amino acid sequences and substrate specificities. Among the PDE families, the PDE4 family, which includes four isoforms named PDE4A, -4B, -4C, and -4D, specifically hydrolyzes cAMP [10, 11]. Several studies have shown that upregulation of PDE4 activity reduces cell sensitivity to the cAMP-elevating reagents such as -agonist [10, 12–14].

We have shown that PGE₂ exposure augments PDE4 activity and induces functional homologous and heterologous attenuation of cAMP-mediated inhibition of fibroblast chemotaxis [15]. Similarly, PDE4 activity induced by PGE₂ is involved in the desensitization of -mimetics in human myometrium during the late stages of pregnancy [16]. Moreover, salbutamol also upregulates PDE4 activity and induces a heterologous desensitization of U937 cells to PGE₂ [14]. Thus, we hypothesize that endogenous and exogenous PGE₂ may reduce sensitivity of the lung fibroblasts to long-acting -agonist through upregulating PDE4.

We have previously reported that -adrenergic agonists and PDE4 inhibitors can modulate fibroblast-mediated collagen gel contraction through the cAMP/PKA pathway [7, 17]. The synergistic effect of -agonist and PDE4 inhibitor on fibroblast-mediated collagen gel contraction and its mechanism, however, has not been investigated. In the current paper, we first studied the effect of varying concentrations of salmeterol plus cilomilast or vice versa on lung fibroblast-mediated collagen gel contraction. Secondly, we studied the role of endogenous and exogenous PGE₂ in regulating the synergistic effect of salmeterol and cilomilast on fibroblast-mediated collagen gel contraction.

2. Materials and Methods

2.1. Materials

Salmeterol and cilomilast were kindly provided by GlaxoSmithKline (Upper Marrion, PA, USA). Indomethacin, PGE₂, and anti--actin antibody were purchased from Sigma (St. Louise, MO, USA). Anti-PDE4 antibodies were purchased from Abcam (PDE4A: cat#: ab14607; PDE4B: cat#: ab14611; PDE4C: cat#: ab97356; PDE4D: cat#: ab14613, Abcam, Inc., Cambridge, MA, USA). Native type I collagen, rat tail tendon collagen (RTTC), was extracted from rat tail tendon as described previously [7].

2.2. Cell Culture

Human fetal lung fibroblast (HFL-1) was purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in DMEM supplemented with 10% FCS, penicillin/streptomycin, and fungizone. Passages of 14 through 20 were used for the experiments.

2.3. Collagen Gel Preparation and Contraction Assay

Gels were prepared using a previously published method [18]. Briefly, distilled water, 4X concentrated DMEM and RTTC were mixed so that the final mixture resulted in a physiological ionic strength, that is, 1X DMEM, and a pH of 7.4. Cells were suspended with serum-free DMEM (SF-DMEM) at a density of 10⁷ cells/mL and then mixed with the RTTC solution mentioned above so that the final cell density in the collagen solution was 4 × 10⁵ cells/mL and the final concentration of collagen was 0.75 mg/mL. For pretreatment with PGE₂ or indomethacin, fibroblast monolayers were refed with SF DMEM supplemented with or without PGE₂ or indomethacin and then incubated for 24 hours prior to harvest. Aliquots of the mixture of fibroblasts and collagen were then cast into each well of a 24-well tissue culture plate (0.5 mL/well). After 20 minutes for gelation at room temperature, the gels were released into 60 mm tissue culture dishes (three gels per each dish), which contained 5 mL of freshly prepared SF-DMEM with or without salmeterol or cilomilast as indicated. The gels were then incubated at 37°C in a 5% CO₂ atmosphere for 2–5 days as indicated, and the area of each gel was measured with an Optomax V Image Analyzer (Optomax, Burlington, MA, USA) daily. Data were expressed as the percentage of the size compared to original gel size.

2.4. Immunoblotting

Immunoblotting for PDE4A, -4B, -4C, -4D and for -actin was carried out with whole cell lysates obtained from the cells pretreated with either PGE₂ or indomethacin for 24 hrs. Briefly, cells were plated into 60 mm dishes and cultured till confluent. Cells were then treated with SF-DMEM supplemented with ethanol (1 : 1000 dilution as reagent dissolvent), PGE₂ (10⁻⁸ M), or indomethacin (10⁻⁶ M). After 24 hrs of culturing, cells were washed once with cold PBS and then treated with cell lysis buffer (35 mM Tris. HCl, pH 7.4, 0.4 mM EGTA, 10 mM MgCl₂, and 1 : 1000 of proteinase inhibitor cocktail). Lysates were briefly sonicated on ice and centrifuged at 10,000 g for 5 min at 4°C. PAGE-SDS (10%) gels were prepared, and 10 μg/lane of total protein was loaded. The resolved proteins were transferred to PVDF membrane and incubated with primary antibodies at 1 : 500 dilution. After incubation with HRP-conjugated 2nd antibodies, images were visualized with Lumigen PS-3 (Beckman, Southfield, MI, USA) and quantified with a Typhon Scanner (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, England, UK).

2.5. Statistical Analysis

All experiments were performed on three separate occasions, each of which included triplicate gels for each condition. All data are expressed as mean ± standard error of the mean. Statistical comparisons of multi-group data were analyzed by analysis of variance (ANOVA) followed by Bonferroni’s (two-way) posttest correction using PRISM4 software.

3. Result

Human lung fibroblast- (HFL-1-) mediated collagen gel contraction, an in vitro model of tissue remodeling, was used to investigate the effect of a cAMP-elevating agent on fibroblast tissue repair functions. The long-acting -agonist salmeterol inhibited fibroblast-mediated collagen gel contraction in a concentration-dependent manner ( M; at concentrations of 10⁻⁷ and 10⁻⁶ M compared to control, Figure 1(a)). By contrast, a PDE4 inhibitor, cilomilast, had no effect on fibroblast-mediated collagen gel contraction when it was added alone at concentrations of 10⁻⁷, 10⁻⁶, and 10⁻⁵ M (Figure 1(b)). When salmeterol (10⁻⁸ M) and cilomilast (10⁻⁶ M), concentrations that were without effect when added alone, were added together, fibroblast-mediated collagen gel contraction was significantly inhibited from day 1 through day 5 (, Figure 1(c)).

(a) Salmeterol

(b) Cilomilast

(c) Sal + cilo

Figure 1: Synergistic effect of salmeterol and cilomilast on lung fibroblast-mediated collagen gel contraction. HFL-1 cells were cast into collagen gels and released into SF-DMEM containing either varying concentrations of salmeterol (0, 10⁻⁸, 10⁻⁷ and 10⁻⁶ M, (a)) or cilomilast (0, 10⁻⁷, 10⁻⁶, and 10⁻⁵ M, (b)) as indicated. Gel size was measured on day 2. Vertical axes: gel size was expressed as percentage of initial size on day 2 (%); horizontal axes: concentrations of salmeterol or cilomilast. *. (c) Synergistic effect of salmeterol and cilomilast are shown. HFL-1 cells were cast into collagen gels and released into SF-DMEM containing salmeterol (10⁻⁸ M) and/or cilomilast (10⁻⁶ M). Gel size was measured daily for 5 days. Vertical axis: gel size was expressed as percentage of initial size (%); horizontal axis: time (day). ** compared to SF-DMEM at each time point.

Next, we examined the combination of varying concentrations of salmeterol plus one concentration of cilomilast, or vice versa, and the resultant effect on collagen gel contraction. In the presence of cilomilast (10⁻⁶ M), lower concentrations of salmeterol (10⁻⁸ and 10⁻⁷ M) significantly (10⁻⁸ M, ; 10⁻⁷ M, ) inhibited fibroblast-mediated collagen gel contraction compared to salmeterol alone (Figure 2(a)). While cilomilast alone at concentrations of  M had no effect on fibroblast-mediated collagen gel contraction, in the presence of a low concentration of salmeterol (10⁻⁸ M) cilomilast at all three concentrations tested (10⁻⁷, 10⁻⁶, and 10⁻⁵ M) significantly inhibited collagen gel contraction (, Figure 2(b)).

(a)

(b)

Figure 2: Cilomilast potentiates the inhibitory effect of salmeterol on fibroblast-mediated collagen gel contraction. (a) Effect of cilomilast on varying concentrations of salmeterol. HFL-1 cells were cast into collagen gels and released into SF-DMEM containing varying concentrations (0, 10⁻⁸, 10⁻⁷, and 10⁻⁶ M) of salmeterol in the presence or absence of cilomilast (10⁻⁶ M). Vertical axis: gel size on day 2 (%); horizontal axis: salmeterol concentration (M). Square: SF-DMEM only; triangle: in the presence of 10⁻⁶ M cilomilast. *; ** compared to salmeterol only. (b) Effect of salmeterol in the presence of varying concentrations of cilomilast. HFL-1 cells containing collagen gels were released into SF-DMEM supplemented with 10⁻⁸ M salmeterol in the presence or absence of varying concentrations (0, 10⁻⁷, 10⁻⁶, and 10⁻⁵ M) of cilomilast. Vertical axis: gel size on day 2 (%); horizontal axis: cilomilast concentrations (M). Square: SF-DMEM only; triangle: in the presence of salmeterol (10⁻⁶ M). ** compared to cilomilast alone at each time point.

Since human lung fibroblasts release PGE₂ and endogenous PGE₂ may modulate the effect of -agonists by modulating the cAMP signaling pathway, HFL-1 cells were pretreated with indomethacin before being cast into the collagen gels. After the pretreatment with indomethacin (10⁻⁶ M) for 24 hours, the inhibitory effect of salmeterol on fibroblast-mediated collagen gel contraction was further significantly potentiated (, Figure 3(a)). By contrast, there was a slight reduction of contraction in the presence of cilomilast that did not reach statistical significance (Figure 3(b)). In addition, indomethacin pretreatment augmented the inhibitory effect of salmeterol and cilomilast added together (, Figure 3(c)).

(a)

(b)

(c)

Figure 3: Indomethacin potentiates salmeterol but not cilomilast. Confluent HFL-1 cells were pretreated with SF-DMEM with or without 10⁻⁶ M indomethacin for 24 hrs. The next day, cells were cast into collagen gels as described in Section 2. (a) Indomethacin pretreatment potentiated the salmeterol effect on fibroblast-mediated collagen gel contraction. Gels were released into SF-DMEM supplemented with varying concentrations of salmeterol as indicated. Vertical axis: gel size on day 2 (%); horizontal axis: salmeterol concentrations (M). Square: cells were cultured in SF-DMEM for 24 hrs prior to being cast into collagen gels; triangle: cells were pretreated with 10⁻⁶ M indomethacin for 24 hrs prior to being cast into collagen gels. * compared to control at each time point. (b) Indomethacin pretreatment did not affect the cilomilast effect. Gels were released into SF-DMEM containing varying concentrations of cilomilast as indicated. Vertical axis: gel size on day 2 (%); horizontal axis: cilomilast concentrations (M). Square: cells were cultured in SF-DMEM for 24 hrs prior to being cast into collagen gels; triangle: cells were pretreated with 1 μM indomethacin for 24 hrs prior to being cast into collagen gels. (c) Indomethacin further potentiated the synergistic effect of salmeterol and cilomilast added together on fibroblast-mediated collagen gel contraction. Gels were released into SF-DMEM with or without salmeterol and/or cilomilast as indicated. Vertical axis: gel size on day 2 (%); horizontal axis: reagents in the medium in which gels were floated. Open bars: cells were cultured in SF-DMEM for 24 hrs prior to being cast into collagen gels; hatched bars: cells were pretreated with 10⁻⁶ M indomethacin for 24 hrs prior to being cast into collagen gels. *; **.

Since the indomethacin pretreatment suggested that endogenous PGE₂ could attenuate the effect of salmeterol and salmeterol plus cilomilast, we next assessed the effect of exogenous PGE₂ in modulating salmeterol and cilomilast inhibition of fibroblast-mediated collagen gel contraction. To accomplish this, HFL-1 cells were pretreated with PGE₂ (10⁻⁹ M) for 24 hrs prior to being cast into collagen gels and exposed to salmeterol and/or cilomilast. PGE₂-pretreated cells contracted gels more than the control did cells (Figure 4(a)). By contrast to indomethacin pretreatment, which potentiated salmeterol inhibition of collagen gel contraction, PGE₂ pretreatment of lung fibroblasts resulted in loss of salmeterol inhibition of fibroblast-mediated collagen gel contraction (Figure 4(a)). By contrast, PGE₂-pretreatment potentiated the effect of cilomilast when added alone, and after PGE₂-pretreatment, the inhibition of fibroblast-mediated collagen gel contraction by cilomilast was statistically significant (, Figure 4(b)). In cells preexposed to PGE₂, salmeterol plus cilomilast also significantly inhibited collagen gel contraction (, Figure 4(c)).

(a)

(b)

(c)

Figure 4: Exogenous PGE₂ pretreatment potentiates cilomilast but not salmeterol. Confluent HFL-1 cells were pretreated with SF-DMEM with or without 10⁻⁹ M PGE₂ for 24 hrs. The next day, cells were cast into collagen gels as described in Section 2. (a) PGE₂ pretreatment abolished the inhibitory effect of salmeterol on collagen gel contraction. (b) PGE₂ pretreatment potentiated the effect of cilomilast in inhibiting collagen gel contraction. (c) Effect of PGE₂ pretreatment on the synergistic effect of salmeterol and cilomilast.

To investigate the mechanism by which endogenous and exogenous PGE₂ modulate long-acting -agonist (salmeterol) and PDE4 inhibitor (cilomilast) inhibition of fibroblast-mediated collagen gel contraction, HFL-1 cells were pretreated with 10⁻⁶ M indomethacin or 10⁻⁹ M PGE₂ for 24 hrs. Whole cell lysate proteins were then extracted and evaluated by immunoblotting for PDE4 isoforms (PDE4A, PDE4B, PDE4C, and PDE4D) with -actin utilized as a loading control. As shown in Figure 5, PDE4A, -4B, and -4C were expressed by HFL-1 cells, while the PDE4D isoform was not expressed (Figure 5(a)). Furthermore, PGE₂ significantly stimulated PDE4A and -4C () expression, while PDE4B was not affected (Figure 5(b)). Indomethacin, by contrast, inhibited PDE4C expression (), but it did not affect PDE4A or -4B.

(a) Western image

(b) Densitometry

Figure 5: Effect of PGE₂ and indomethacin on PDE4 expression. Confluent HFL-1 cells were treated with SF-DMEM with or without 10⁻⁹ M PGE₂ or 10⁻⁶ M indomethacin for 24 hrs. Whole cell lysates were immunoblotted for PDE4 isoforms and -actin as loading control. Images were visualized with ECL plus (a), and the bands from 3 separate experiments were quantified (b). *.

4. Discussion

Fibroblast-mediated collagen gel contraction is widely used as an in vitro model of tissue remodeling. In the current study, using this in vitro model of tissue remodeling, we have demonstrated a synergistic effect of the long-acting -agonist salmeterol and the PDE4 inhibitor cilomilast in inhibiting fibroblast-mediated collagen gel contraction. In addition, we have demonstrated that this interaction is modulated by both endogenous and exogenous PGE₂. Finally, we have demonstrated that PGE₂ modulates the expression of several PDE4 isoforms, providing a mechanism for regulating the synergistic interaction of salmeterol and cilomilast.

Consistent with a previous report [7], the long-acting -agonist, salmeterol, inhibited fibroblast-mediated collagen gel contraction at concentrations of 10⁻⁷ and 10⁻⁶ M. The PDE4 inhibitor, cilomilast alone, did not affect fibroblast-mediated collagen gel contraction at concentrations of 10⁻⁷, 10⁻⁶, and 10⁻⁵ M. However, when added together, 10⁻⁸ M salmeterol and cilomilast (10⁻⁷, 10⁻⁶, and 10⁻⁵ M) significantly inhibited collagen gel contraction. Since neither agent alone resulted in inhibition, this demonstrates synergy between these agents. This is consistent with the known role of these agents in modulating cAMP. Salmeterol increases cAMP, and PDE4 degrades cAMP to AMP [19–21]. Cilomilast, by blocking cAMP degradation, could permit accumulation of cAMP concentrations sufficient to inhibit gel contraction in response to concentrations of salmeterol that could not achieve such concentrations alone. Consistent with this, 10⁻⁶ M cilomilast also potentiated the actions of higher concentrations of salmeterol (10⁻⁸ and 10⁻⁷ M) in inhibiting collagen gel contraction.

Several studies have demonstrated that agents that increase cAMP can induce PDE activity [14, 22–28]. Consistent with these studies, pretreatment of the fibroblasts with 10⁻⁶ M indomethacin for 24 hrs prior to being cast into collagen gels resulted in further inhibition of collagen gel contraction by salmeterol added alone, consistent loss of PDE activity. In contrast, pretreatment with indomethacin did not affect contraction in the presence of cilomilast.

This contrasts with the effect of pretreatment of the fibroblasts with 10⁻⁹ M PGE₂. Interestingly, pretreatment with PGE₂ resulted in augmentation of contraction. The mechanism of this effect of PGE₂ pretreatment is not defined, but it resembles the results of Michalski who observed augmentation of chemotaxis following PGE₂ pretreatment [15]. PGE₂ pretreatment also changed the response of the fibroblasts to salmeterol and cilomilast added alone. By contrast to control cells, following PGE₂ pretreatment, cilomilast added alone significantly inhibited gel contraction while salmeterol was without significant effect. This is consistent with the previously observed increase in PDE activity observed in a variety of cell types in response to increases in cAMP [14, 22–28]. Also consistent with such a mechanism, we observed that PDE4C was significantly decreased when the cells were pretreated with indomethacin, while, by contrast, PDE4A and PDE4C were significantly increased when the cells were pretreated with PGE₂.

Fibroblasts play an important role in tissue remodeling [2]. Long-acting -agonists are widely used in treating COPD for their bronchodilator action [29]. Recently, a PDE4 inhibitor has been approved for use in selected COPD patients to reduce exacerbation risk [30]. Both -agonists and PDE4 inhibitors have the potential to modulate tissue remodeling. Long-acting -agonists have the potential to modulate fibroblast tissue remodeling through inhibiting fibroblast proliferation, differentiation, and collagen production through mechanisms that depend on increasing intracellular cAMP [31]. Phosphodiesterases (PDEs), especially PDE4, may also modulate fibroblast-mediated tissue remodeling by increasing intracellular cAMP levels. In this regard, we have previously reported that -agonists and PDE4 inhibitors could inhibit human lung fibroblast-mediated collagen gel contraction, a widely used model of the tissue contraction that characterizes tissue remodeling [7, 17]. Synergy between a -agonist and a PDE4 inhibitor on fibroblast-mediated collagen gel contraction, however, has not been previously demonstrated. The current study demonstrates such synergy.

The present study provides an explanation for differences among prior studies. We have previously reported that cilomilast alone at the concentrations of  M inhibited fibroblast migration and collagen gel contraction [17], while the same concentrations of cilomilast did not alter fibroblast-mediated collagen gel contraction in the current study. These differing results are likely due to different experimental designs. In the previous report on cilomilast modulation of fibroblast-mediated collagen gel contraction [17], 0.5% FCS was added to the medium in which gels were floated. In the current study, however, there was no serum in the medium in which gels were floated. While the effect of serum is not clear, the current study clearly shows that PGE₂ can modulate cilomilast responsiveness. Cells pretreated with PGE₂ were responsive to cilomilast inhibition, which is consistent with PGE₂ induction of PDE expression.

Conversely, cells pretreated with PGE₂ became unresponsive to salmeterol. Consistent with this resulting from the induction of PDE4, the synergistic effect of cilomilast added together with salmeterol was also observed in PGE₂ pretreated cells. Lung fibroblasts synthesize and release PGE₂ [9], and the current study also provides evidence that endogenous PGE₂ can modulate -agonist signaling by affecting PDE4 isoform expression.

Consistent with previous reports [17], HFL-1 cells expressed predominantly PDE4A, -4B, and -4C but not PDE4D. Interestingly, indomethacin significantly inhibited PDE4C expression, while PGE₂ significantly stimulated PDE4A and -4C. These findings indicate that PGE₂, by augmenting PDE4 expression, may accelerate cAMP degradation. Consistent with our findings, it has also been reported that PGE₂ upregulates PDE4 activity through induction of enzyme synthesis in the myometrium, and by this mechanism PGE₂ lessens the responsiveness of myometrium to -mimetic activation [16, 22].

Taken together, these results suggest that PDE4 is upregulated by both endogenous and exogenous PGE₂. In the presence of low levels of PDE4, -agonist (but not PDE inhibitor) can inhibit collagen gel contraction. When PDE4 levels are augmented, however, -agonist becomes less effective since PDE4 results in degradation of any cAMP generated. This loss of responsiveness to -agonist may be particularly important in an inflammatory milieu such as that which exists in COPD where PGE levels are high [32–34]. When added together, there is synergy between -agonist and PDE inhibitor. This suggests that the synergy between PDE4 inhibition and -agonists may be particularly important in COPD where high levels of PGE are present.

In summary, the current paper demonstrates synergy between a long-acting -agonist (salmeterol) and a PDE4 inhibitor (cilomilast) in their ability to inhibit fibroblast-mediated collagen gel contraction, a widely used model of tissue remodeling. Through such an action, these agents, which are currently in use to treat COPD, could also alter the tissue remodeling present in COPD. In addition, the current study demonstrates that PDE4 expression in lung fibroblasts is induced by PGE₂ suggesting that this synergy may be particularly important in inflammatory diseases such as COPD where PGE levels are high.

Conflict of Interests

Qiuhong Fang, Yingmin Ma, Jing Wang, and Joel Michalski declare no conflict of interests. Xiangde Liu received a research grant from GlaxoSmithKline. Stephen I. Rennard received fees for serving on advisory boards, consulting, or honoraria from Almirall, APT Pharma, Aradigm, Argenta, AstraZeneca, Boehringer Ingelheim, Chiesi, Dey, Forest, GlaxoSmithKline, Hoffmann-La Roche, MedImmune, Mpex, Novartis, Nycomed, Oriel, Otsuka, Pearl, Pfizer, Pharmaxis, Merck, and Talecris.

Acknowledgments

The authors happily thank Ms. Lillian Richards for assistance with the paper. This study was supported by a Grant from the GSK (SER-R54/101187) and by the Larson Endowment, University of Nebraska Medical Center, Omaha, NE, USA.

References

S. D. Shapiro, J. J. J. Reilly, and S. I. Rennard, “Chronic bronchitis and emphysema,” in Textbook of Respiratory Medicine, R. J. Mason, V. C. Broaddus, T. R. Martin et al., Eds., vol. 1, pp. 919–967, Saunders, Philadelphia, Pa, USA, 2010.

S. I. Rennard and K. von Wachenfeldt, “Rationale and emerging approaches for targeting lung repair and regeneration in the treatment of chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 8, no. 4, pp. 368–375, 2011.

X. Liu, H. Conner, T. Kobayashi et al., “Synergetic effect of interleukin-4 and transforming growth factor-β1 on type I collagen gel contraction and degradation by HFL-1 cells: implication in tissue remodeling,” Chest, vol. 123, no. 3, pp. 427S–428S, 2003.

P. Ngo, P. Ramalingam, J. A. Phillips, and G. T. Furuta, “Collagen gel contraction assay,” Methods in Molecular Biology, vol. 341, pp. 103–109, 2006.

M. Abe, C. Ho, K. E. Kamm, and F. Grinnell, “Different molecular motors mediate platelet-derived growth factor and lysophosphatidic acid-stimulated floating collagen matrix contraction,” The Journal of Biological Chemistry, vol. 278, no. 48, pp. 47707–47712, 2003.

X. Liu, T. Umino, M. Cano et al., “Human bronchial epithelial cells can contract type I collagen gels,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 274, no. 1, pp. L58–L65, 1998.

T. Mio, Y. Adachi, S. Carnevali, D. J. Romberger, J. R. Spurzem, and S. I. Rennard, “β-adrenergic agonists attenuate fibroblast-mediated contraction of released collagen gels,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 270, no. 5, pp. L829–L835, 1996.

Y. K. Zhu, X. D. Liu, M. C. Sköld et al., “Cytokine inhibition of fibroblast-induced gel contraction is mediated by PGE2 and NO acting through separate parallel pathways,” The American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 2, pp. 245–253, 2001.

P. D. Bozyk and B. B. Moore, “Prostaglandin E2 and the pathogenesis of pulmonary fibrosis,” The American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 3, pp. 445–452, 2011.

M. Conti, W. Richter, C. Mehats, G. Livera, J. Park, and C. Jin, “Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling,” The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5493–5496, 2003.

M. Conti and J. Beavo, “Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling,” Annual Review of Biochemistry, vol. 76, pp. 481–511, 2007.

M. A. Giembycz, “Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma,” Trends in Pharmacological Sciences, vol. 17, no. 9, pp. 331–336, 1996.

J. V. Swinnen, B. D'Souza, M. Conti, and M. Ascoli, “Attenuation of cAMP-mediated responses in MA-10 Leydig tumor cells by genetic manipulation of a cAMP-phosphodiesterase,” The Journal of Biological Chemistry, vol. 266, no. 22, pp. 14383–14389, 1991.

T. J. Torphy, H. L. Zhou, J. J. Foley, H. M. Sarau, C. D. Manning, and M. S. Barnette, “Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of β-adrenoceptor agonists,” The Journal of Biological Chemistry, vol. 270, no. 40, pp. 23598–23604, 1995.

J. Michalski, N. Kanaji, X. Liu et al., “Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4,” The American Journal of Respiratory Cell and Molecular Biology, vol. 47, no. 6, pp. 729–737, 2012.

C. Méhats, G. Tanguy, E. Dallot, D. Cabrol, F. Ferré, and M. Leroy, “Is up-regulation of phosphodiesterase 4 activity by PGE2 involved in the desensitization of β-mimetics in late pregnancy human myometrium?” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5358–5365, 2001.

T. Kohyama, X. Liu, F. Wen et al., “PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels,” The American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 6, pp. 694–701, 2002.

T. Mio, X. Liu, M. L. Toews, and S. I. Rennard, “Lysophosphatidic acid augments fibroblast-mediated contraction of released collagen gels,” Journal of Laboratory and Clinical Medicine, vol. 139, no. 1, pp. 20–27, 2002.

M. Johnson and S. Rennard, “Alternative mechanisms for long-acting β2-adrenergic agonists in COPD,” Chest, vol. 120, no. 1, pp. 258–270, 2001.

M. Johnson, “The β-adrenoceptor,” The American Journal of Respiratory and Critical Care Medicine, vol. 158, supplement 2, pp. S146–S153, 1998.

K. F. Chung, “Phosphodiesterase inhibitors in airways disease,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 110–117, 2006.

C. Méhats, G. Tanguy, E. Dallot et al., “Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMp content in human myometrial cells in culture,” Endocrinology, vol. 140, no. 7, pp. 3228–3237, 1999.

C. D'Sa, L. M. Tolbert, M. Conti, and R. S. Duman, “Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons,” Journal of Neurochemistry, vol. 81, no. 4, pp. 745–757, 2002.

I. R. Le Jeune, M. Shepherd, G. van Heeke, M. D. Houslay, and I. P. Hall, “Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells: identification and characterization of a novel PDE4D5 promoter,” The Journal of Biological Chemistry, vol. 277, no. 39, pp. 35980–35989, 2002.

B. Zhu, J. Kelly, L. Vemavarapu, W. J. Thompson, and S. J. Strada, “Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells,” Biochemical Pharmacology, vol. 68, no. 3, pp. 479–491, 2004.

D. G. Tilley and D. H. Maurice, “Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function,” Molecular Pharmacology, vol. 68, no. 3, pp. 596–605, 2005.

A. Hu, G. Nino, J. S. Grunstein, S. Fatma, and M. M. Grunstein, “Prolonged heterologous β2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1055–L1067, 2008.

G. Nino, A. Hu, J. S. Grunstein, and M. M. Grunstein, “Mechanism regulating proasthmatic effects of prolonged homologous β2-adrenergic receptor desensitization in airway smooth muscle,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 297, no. 4, pp. L746–L757, 2009.

S. I. Rennard, “Treatment of stable chronic obstructive pulmonary disease,” The Lancet, vol. 364, no. 9436, pp. 791–802, 2004.

N. J. Gross, M. A. Giembycz, and S. I. Rennard, “Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor,” COPD, vol. 7, no. 2, pp. 141–153, 2010.

F. Lamyel, M. Warnken-Uhlich, W. K. Seemann et al., “The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 384, no. 2, pp. 133–145, 2011.

P. Montuschi, S. A. Kharitonov, G. Ciabattoni, and P. J. Barnes, “Exhaled leukotrienes and prostaglandins in COPD,” Thorax, vol. 58, no. 7, pp. 585–588, 2003.

Y. Chen, P. Chen, M. Hanaoka, Y. Droma, and K. Kubo, “Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD,” Respirology, vol. 13, no. 7, pp. 1014–1021, 2008.

M. Profita, A. Sala, A. Bonanno et al., “Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 298, no. 2, pp. L261–L269, 2010.